Image Source: Zacks Investment Research Spikevax, targeting the variant JN.1., is currently approved in the United States, the United Kingdom, Japan and Taiwan. Last month, the FDA approved ...

The 2024-2025 formula authorized in August 2024 targets the KP.2 Omicron variant. The Moderna vaccine, also known as Spikevax, has been FDA-approved for use in the U.S. since January 2022 for the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted Moderna COVID-19 vaccine (Spikevax) that targets the JN.1 COVID-19 subvariant. This vaccine is licensed for ...

For the first time in the UK, the updated vaccine, Spikevax® JN.1, will also be available to purchase privately for those who are not eligible for the NHS Autumn vaccination program. The updated ...

has approved an updated formulation of the COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1., for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals ...

The emergency use authorisation from the FDA allows for Novavax’s updated Covid-19 vaccine to be used in individuals 12 years and older. Credit: Aha-Soft / Shutterstock. Novavax has joined its peers ...

Please report side effects. See the full CMI for further details. 1. Why am I being given SPIKEVAX BIVALENT ORIGINAL/ OMICRON BA.4-5? SPIKEVAX BIVALENT ORIGINAL/ OMICRON BA.4-5 contains the active ...

Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA - Moderna's Spikevax and Comirnaty, which is jointly developed by Pfizer ...